Valeant Pharmaceuticals Intl Inc’s (VRX) Bausch + Lomb Launches Biotrue ONEday in Europe

Bausch + Lomb, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 countries in Europe. This latest contact lens advancement provides the convenience of a daily disposable with the innovation of an evolved peri-ballast design for stability and a unique dehydration barrier proven to help the lens maintain 98% of its moisture for up to 16 hours.

“The Biotrue® ONEday for Astigmatism contact lenses were developed by our in-house team of scientists and contact lens designers to meet the needs of today’s astigmatic patients,” said Joseph C. Papa, chairman and CEO, Valeant. “The full spectrum of Biotrue® ONEday products, which also includes Biotrue® ONEday Single Vision and Biotrue® ONEday for Presbyopia contact lenses, is now an option for patients across many countries in Europe.”

As part of the development process for the lens, Bausch + Lomb evaluated various ballasting mechanisms and assessed dynamics of blink patterns across a wide range of patients using high speed videography. To achieve the combination that performed the best in the high-water content material of Biotrue® ONEday contact lenses, engineers created an evolved lens design incorporating advanced optics to help reduce halos and glare, even in low-light conditions.

Shares of Valeant are currently trading at $14.65, up $0.03 or 0.21%. VRX has a 1-year high of $24.89 and a 1-year low of $8.31. The stock’s 50-day moving average is $13.97 and its 200-day moving average is $13.35.

On the ratings front, VRX stock has been the subject of a number of recent research reports. In a report released yesterday, Cantor analyst Louise Chen reiterated a Buy rating on VRX, with a price target of $23, which implies an upside of 57% from current levels. Separately, on the same day, RBC’s Nicholas Keher reiterated a Hold rating on the stock and has a price target of $21.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Louise Chen and Nicholas Keher have a yearly average loss of 8.3% and a return of 1.1% respectively. Chen has a success rate of 42% and is ranked #4564 out of 4686 analysts, while Keher has a success rate of 60% and is ranked #2928.

Overall, 3 research analysts have rated the stock with a Sell rating, 8 research analysts have assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $21.50 which is 47% above where the stock opened today.

Valeant engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S. Diversified products. The Bausch + Lomb/International segment is consist of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment is comprised of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The U.S. Diversified Products segment is the sales in the U.S. of pharmaceutical products, over-the-counter products, and medical device products in the areas of neurology and certain other therapeutics classes, including aesthetics and generic products in the U.S.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts